Data from the National Health Authority shows that nearly 6.5 lakh elderly individuals have successfully enrolled and ...
PTC Therapeutics’ gene therapy, Kebilidi to treat AADC deficiency receives US FDA approval: Warren, New Jersey Friday, November 15, 2024, 10:00 Hrs [IST] PTC Therapeutics, Inc., ...
Becca Ziegler is only 24, but she already has her death planned out: her corpse will be deep-frozen to minus 200 degrees ...
It has been just a few weeks shy of four full years since Purdue lost a regular-season nonconference game. The Boilermakers have run through their nonconference schedule undefeated for three straight ...
Kebilidi is the first approved gene therapy that can be directly administered to the brain. Its OK secures a priority review ...
The Food and Drug Administration (FDA) has granted accelerated approval to Kebilidi™ (eladocagene exuparvovec-tneq) for the treatment of adult and pediatric patients with aromatic L-amino acid ...
The No. 13-ranked Purdue men's basketball team wraps up its season-long, four-game homestand with its toughest opponent to ...
Stephen Miller is one of three immigration hard-liners Trump has named to oversee the implementation of his second term ...
PTC Therapeutics' Kebilidi gains FDA accelerated approval as the first brain-administered gene therapy in the U.S. for AADC ...
16h
Leerink Partners analyst Lili (Aurélie) Nsongo has reiterated their bullish stance on VYGR stock, giving a Buy rating yesterday.
This is the first gene therapy for AADC deficiency to receive US regulatory approval and the first that can be administered directly to the brain.
The drug is a treatment for a rare and fatal genetic disorder called aromatic l-amino acid decarboxylase (AADC) deficiency, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback